by The SUN
 |
| Lau says Sinovac's vaccine is 62.3% effective after the second dose |
A panel of experts has unanimously approved the use of
Coronavac, the vaccine developed by mainland firm Sinovac, for emergency use in
Panel convenor Prof Wallace Lau said in a press briefing this evening that Sinovac had provided them with data from its late-stage trials showing that its vaccine’s benefits outweighed the risks.
 |
| Pindutin para sa detalye! |
Lau said the data showed the vaccine’s efficacy rate is 62.3 percent, when two doses are administered 28 days apart.
Data earlier submitted by Sinovac also indicated the vaccine could trigger an immune response and created antibodies in adults and the elderly.
 |
| Call us! |
Previously, the panel cited late-stage clinical trials in
Lau said the data they got laid those fears to rest.
 |
| CONTACT US! |
“This is about an emergency use of a vaccine that will
hopefully help to protect the people of
The World Health Organization has yet to approve the Sinovac vaccine, but has already set a minimum standard of 50% efficacy rate for all Covid-19 vaccines.
 |
| All Covid-19 vaccines must be at least 50% effective, says the WHO |
Lau brushed off suggestions the 12-member panel of experts bowed to pressure from the government in recommending the use of Sinovac’s vaccine.
 |
| PRESS FOR MORE DETAILS |
“There is no pressure at all from anyone. Over the last few days, I have more or less shut myself down from all the newspapers, etc. We have concentrated primarily on looking at the data,” he said.
Sinovac was supposed to deliver the first million doses of
its vaccine to
 |
| Tunghayan ang isa na namang kwentong Dream Love |
The vaccine developed by German firm BioNTech is on track to
deliver its first batch of jabs to
Hong Kong has procured 7.5 million doses each from Sinovac,
BioNTech, and AstraZeneca in
 |
| CALL US NOW! |
